{"DataElement":{"publicId":"3145850","version":"1","preferredName":"Endocrine Therapy Second Cycle Agent Name","preferredDefinition":"the name of the endocrine therapeutic agent, treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level, administered during the second course or cycle of therapy.","longName":"3145824v1.0:3145835v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3145824","version":"1","preferredName":"Endocrine Therapy Second Cycle Agent","preferredDefinition":"information related to the endocrine therapeutic agent, treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level, administered during the second course or cycle of therapy.","longName":"2433915v1.0:3145815v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2433915","version":"1","preferredName":"Hormone Therapy","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA8-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3145815","version":"1","preferredName":"Second Cycle Agent","preferredDefinition":"Coming next after the first in position in space or time or degree or magnitude.:An event or sequence of events that constitute round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25666:C25472:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Second","conceptCode":"C25666","definition":"Coming next after the first in position in space or time or degree or magnitude.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cycle","conceptCode":"C25472","definition":"An event or sequence of events that constitute a round or succession of observable phenomena, recurring usually at regular or approximately regular time intervals and in the same sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CF7D1C-ECDE-83FE-E040-BB89AD430179","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFC00C-444C-580A-E040-BB89AD4365EE","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3145835","version":"1","preferredName":"Endocrine Therapy Agent Name","preferredDefinition":"the name of the endocrine therapy agent.","longName":"3145835v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Ovarian Function Suppression (OFS) - Medical suppression","valueDescription":"Ovarian Function Suppression (OFS) - Medical suppression","ValueMeaning":{"publicId":"3145836","version":"1","preferredName":"Ovarian Function Suppression (OFS) - Medical suppression","longName":"3145836","preferredDefinition":"Ovarian Function Suppression (OFS) - Medical suppression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A2AD-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A2C6-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Ovarian Function Suppression (OFS) - Oophorectomy","valueDescription":"Ovarian Function Suppression (OFS) - Oophorectomy","ValueMeaning":{"publicId":"3145837","version":"1","preferredName":"Ovarian Function Suppression (OFS) - Oophorectomy","longName":"3145837","preferredDefinition":"Ovarian Function Suppression (OFS) - Oophorectomy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A2D0-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A2E9-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Ovarian Function Suppression (OFS) - Ovarian radiation","valueDescription":"Ovarian Function Suppression (OFS) - Ovarian radiation","ValueMeaning":{"publicId":"3145838","version":"1","preferredName":"Ovarian Function Suppression (OFS) - Ovarian radiation","longName":"3145838","preferredDefinition":"Ovarian Function Suppression (OFS) - Ovarian radiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A2F3-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A30C-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Aromatase Inhibitor - Exemestane (Aromasin)","valueDescription":"Aromatase Inhibitor - Exemestane (Aromasin)","ValueMeaning":{"publicId":"3145839","version":"1","preferredName":"Aromatase Inhibitor - Exemestane (Aromasin)","longName":"3145839","preferredDefinition":"Aromatase Inhibitor - Exemestane (Aromasin)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A316-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A32F-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Aromatase Inhibitor - Letrozole (Femara)","valueDescription":"Aromatase Inhibitor - Letrozole (Femara)","ValueMeaning":{"publicId":"3145840","version":"1","preferredName":"Aromatase Inhibitor - Letrozole (Femara)","longName":"3145840","preferredDefinition":"Aromatase Inhibitor - Letrozole (Femara)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A339-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A352-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Aromatase Inhibitor - Anastrazole (Arimidex)","valueDescription":"Aromatase Inhibitor - Anastrazole (Arimidex)","ValueMeaning":{"publicId":"3145841","version":"1","preferredName":"Aromatase Inhibitor - Anastrazole (Arimidex)","longName":"3145841","preferredDefinition":"Aromatase Inhibitor - Anastrazole (Arimidex)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A35C-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A375-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Anastrozole","valueDescription":"Anastrozole","ValueMeaning":{"publicId":"3145842","version":"1","preferredName":"Anastrozole","longName":"3145842","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A37F-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A398-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Letrozole","valueDescription":"Letrozole","ValueMeaning":{"publicId":"2921027","version":"1","preferredName":"Letrozole","longName":"2921027","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD52-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A3A2-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Exemestane","valueDescription":"Exemestane","ValueMeaning":{"publicId":"3145843","version":"1","preferredName":"Exemestane","longName":"3145843","preferredDefinition":"A synthetic androgen analogue.  Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exemestane","conceptCode":"C1097","definition":"An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A3AC-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A3C5-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Fulvestrant","valueDescription":"Fulvestrant","ValueMeaning":{"publicId":"2575943","version":"1","preferredName":"Fulvestrant","longName":"2575943","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A3CF-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"Tamoxifen","ValueMeaning":{"publicId":"2897675","version":"1","preferredName":"Tamoxifen","longName":"2897675","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B75B6A8-FB2B-BC7B-E040-BB89AD4323EC","latestVersionIndicator":"Yes","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"FINCHAMB","dateModified":"2022-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A3D9-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Toremifene","valueDescription":"Toremifene","ValueMeaning":{"publicId":"3145844","version":"1","preferredName":"Toremifene","longName":"3145844","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antiestrogens. Toremifene blocks the effect of the hormone estrogen in the body. It may help control some cancers from growing, and it may delay or reduce the risk of cancer recurrence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toremifene","conceptCode":"C1256","definition":"A nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A3E3-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A3FC-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Megestrol Acetate","valueDescription":"Megestrol Acetate","ValueMeaning":{"publicId":"2580127","version":"1","preferredName":"Megestrol Acetate","longName":"2580127","preferredDefinition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with anti-estrogenic activity and used in breast cancer treatment. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol Acetate","conceptCode":"C1156","definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-060C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"ONEDATA","dateModified":"2006-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A410-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Fluoxymesterone","valueDescription":"Fluoxymesterone","ValueMeaning":{"publicId":"2576869","version":"1","preferredName":"Fluoxymesterone","longName":"2576869","preferredDefinition":"An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluoxymesterone","conceptCode":"C507","definition":"A halogenated derivative of 17-alpha-methyltestosterone.  Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus.  This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F952-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A41A-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Ethinyl Estradiol","valueDescription":"Ethinyl Estradiol","ValueMeaning":{"publicId":"2576830","version":"1","preferredName":"Ethinyl Estradiol","longName":"2576830","preferredDefinition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol","conceptCode":"C486","definition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A424-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3089560","version":"1","preferredName":"Other","longName":"3089560","preferredDefinition":"Other treatment cannot be appropriately assigned to specific data item (i.e. phlebotomy, transfusion, and aspirin or other disease modifying agent). Use for hematopoietic diseases.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87063ADB-2EE9-3A83-E040-BB89AD430877","latestVersionIndicator":"Yes","beginDate":"2010-05-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-05-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91CFFC87-A42F-4714-E040-BB89AD4352D5","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"ONEDATA","dateModified":"2010-10-04","deletedIndicator":"No"},{"value":"Tamoxifen followed by an AI","valueDescription":"Tamoxifen Angiogenesis Inhibitor","ValueMeaning":{"publicId":"3717857","version":"1","preferredName":"Tamoxifen Angiogenesis Inhibitor","longName":"3717857","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04): An agent or endogenous substance that inhibits the formation and growth of blood or lymphatic vessels.  In cancer therapy, angiogenesis inhibitors target blood vessels that supply tumors, thereby inhibiting tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Angiogenesis Inhibitor","conceptCode":"C1742","definition":"An agent or endogenous substance that inhibits the formation of capillaries from existing blood vessels. In cancer therapy, angiogenesis inhibitors preferentially target the new blood vessels that tumors require for oxygen and nutrition, thereby inhibiting the growth and spread of these tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D98E1C7E-4138-3CC6-E040-BB89AD4330B4","latestVersionIndicator":"Yes","beginDate":"2013-04-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA2A6778-3C4E-51AD-E040-BB89AD437E3F","beginDate":"2013-04-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-04-12","modifiedBy":"ONEDATA","dateModified":"2013-04-12","deletedIndicator":"No"},{"value":"N/A","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5682946","version":"1","preferredName":"Not Applicable","longName":"5682946v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9B2B-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":"2023.8.15 Alt VM added per ticket request CADSR0002731. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA2F13F-6EE7-32B3-E053-F662850ADC7A","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Nolvadex","valueDescription":"Tamoxifen Citrate","ValueMeaning":{"publicId":"5294355","version":"1","preferredName":"Tamoxifen Citrate","longName":"5294355","preferredDefinition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3557625D-6251-3A11-E050-BB89AD435F94","latestVersionIndicator":"Yes","beginDate":"2016-06-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA2F13F-6EFC-32B3-E053-F662850ADC7A","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Faslodex","valueDescription":"Fulvestrant","ValueMeaning":{"publicId":"2575943","version":"1","preferredName":"Fulvestrant","longName":"2575943","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA2F13F-6F11-32B3-E053-F662850ADC7A","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Fareston","valueDescription":"Toremifene Citrate","ValueMeaning":{"publicId":"4111916","version":"1","preferredName":"Toremifene Citrate","longName":"4111916","preferredDefinition":"The citrate salt of a nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which is manifested depending on the tissue or species. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toremifene Citrate","conceptCode":"C1756","definition":"The citrate salt of a nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which is manifested depending on the tissue or species. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F0A6CACD-1511-467D-E040-BB89AD432147","latestVersionIndicator":"Yes","beginDate":"2014-01-23","endDate":null,"createdBy":"BASSG","dateCreated":"2014-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA2F13F-6F25-32B3-E053-F662850ADC7A","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Evista","valueDescription":"Raloxifene Hydrochloride","ValueMeaning":{"publicId":"3379522","version":"1","preferredName":"Raloxifene Hydrochloride","longName":"3379522","preferredDefinition":"The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raloxifene Hydrochloride","conceptCode":"C1762","definition":"The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3249-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA2F13F-6F39-32B3-E053-F662850ADC7A","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Aromatase Inhibitor","valueDescription":null,"ValueMeaning":{"publicId":"2897676","version":"1","preferredName":"Aromatase Inhibitor","longName":"2897676","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B75B6A8-FB4E-BC7B-E040-BB89AD4323EC","latestVersionIndicator":"Yes","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"FINCHAMB","dateModified":"2022-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ED9A29E8-91CF-506B-E053-731AD00A399C","beginDate":"2022-11-16","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-16","modifiedBy":"GDEEN","dateModified":"2022-11-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A298-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"GDEEN","dateModified":"2022-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Hormone Therapy Course 2","type":"Preferred Question Text","description":"Hormone Therapy Course 2","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A4D4-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"CAMPBELB","dateModified":"2010-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}